LEASE by and between BMR-HAMPSHIRE LLC, a Delaware limited liability company and EPIZYME, INC., a Delaware corporationLease • October 31st, 2019 • Epizyme, Inc. • Pharmaceutical preparations
THIS LEASE (this “Lease”) is entered into as of this 1st day of October, 2019 (the “Execution Date”), by and between BMR-HAMPSHIRE LLC, a Delaware limited liability company (“Landlord”), and EPIZYME, INC., a Delaware corporation (“Tenant”).
FOURTH AMENDMENT TO COMPANION DIAGNOSTICS AGREEMENTCompanion Diagnostics Agreement • October 31st, 2019 • Epizyme, Inc. • Pharmaceutical preparations
This Fourth Amendment (“Fourth Amendment”) shall be effective as of this 26 day of July, 2019 (“Amendment Effective Date”), by and between Epizyme, Inc., having a place of business at 400 Technology Square, 4th Floor, Cambridge, Massachusetts 02139, U.S.A. (“Epizyme”) and Eisai Co., Ltd., having a place of business at Koshikawa 4-6-10, Bunkyo-ku, Tokyo 112-8088, Japan (individually “Eisai” and collectively with Epizyme, “Pharmaceutical Partners”), on the one side, and Roche Molecular Systems, Inc., having a place of business at 4300 Hacienda Drive, Pleasanton, California 94588, U.S.A (“RMS”) and Roche Sequencing Solutions, Inc., having a place of business at 4300 Hacienda Drive, Pleasanton, California 94588, U.S.A (“RSS”), on the other side, as an amendment to the Companion Diagnostics Agreement dated 18 December 2012, as first amended on 31 May 2013, second amended on 16 November 2015 (the “Second Amendment”), and third amended on 7 March 2018 (the “Third Amendment”) (collectively, th
